about
Characterization of somatic cell nuclear reprogramming by oocytes in which a linker histone is required for pluripotency gene reactivation.Histone variant macroH2A confers resistance to nuclear reprogramming.Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort studyImpact of antiretroviral therapy on health-related quality of life among South African women in the CAPRISA 002 acute infection study.Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testingSouth African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting.Epigenetic stability of repressed states involving the histone variant macroH2A revealed by nuclear transfer to Xenopus oocytes.Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor AgonistsTargeted screening of at-risk adults for acute HIV-1 infection in sub-Saharan Africa.Widespread transcription in an amphibian oocyte relates to its reprogramming activity on transplanted somatic nuclei.Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypesEffect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African WomenEfficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.Acceptability of Early Antiretroviral Therapy Among South African Women.Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women.Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants.Tpt1 activates transcription of oct4 and nanog in transplanted somatic nucleiProtocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREAtment and Monitoring (STREAM) study.HIRA dependent H3.3 deposition is required for transcriptional reprogramming following nuclear transfer to Xenopus oocytes.Opportunities for earlier diagnosis of HIV in general practice.Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.Raltegravir treatment response in an HIV-2 infected patient: a case report.Integrin α4β7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes.Point-of-care viral load testing and differentiated HIV care.Computational analysis of antibody dynamics identifies recent HIV-1 infection.Impact of an educational video as a consent tool on knowledge about cure research among patients and caregivers at HIV clinics in South Africa.Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries.HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.Clinic-Based Evaluation of a Point-of-Care Creatinine Assay to Screen for Renal Impairment Among HIV-Positive Patients Receiving Tenofovir Disoproxil Fumarate.Clinic flow for STI, HIV, and TB patients in an urban infectious disease clinic offering point-of-care testing services in Durban, South Africa.Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection.HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization BreadthDolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and researchV2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC ActivityThe Replication-Competent HIV-1 Latent Reservoir is Primarily Established Near the Time of Therapy Initiation: Supplemental Material for Abrahams et alPositive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies
P50
Q30493994-ADA85CBC-A0E9-4624-8B79-B3077051B158Q30501191-DAD1C5DE-D75D-4A65-9B91-C2AA04E4B87DQ33610865-21BC517D-6F68-48C6-8B76-ACAF2B7EC39CQ34021927-A3822F10-3132-4B45-8485-5D2792A71717Q34706934-904E638B-5B14-457B-A3F0-76D3843C5877Q35672336-8A0139F9-717B-48D4-A51C-D2744A622587Q35862772-4C15A620-FA80-4AE9-B3F6-79E98BBF602CQ35883251-CE3796CE-708D-4BA0-9062-B904A66442B4Q35883727-A18B66B2-BE17-4E9B-8A6F-C2347DF28BF8Q35965218-FABB2FFF-5161-4A9D-BA2B-26B31D6F3259Q36015881-B57DA7DA-3F72-428F-993F-01608D25BA5AQ36468175-7160EE83-7984-489D-B823-C82BC4F11FD4Q36795465-7C92D5B0-96D0-4357-9678-2DEFB085EE82Q37047737-685F4888-F32B-474C-8296-27B8768AD31FQ39048750-E5E1E373-0B74-496C-B85E-C8E1313A1FB4Q39195695-92B4D975-8849-40D7-A1F1-B7D4CAE552BBQ40324514-60C0DE52-987D-424B-AA7F-6DE92126D529Q40349815-253CF79C-A25D-42DF-B18E-6FD4FF38F414Q40501405-807ADECA-3D8F-4B66-B589-A6DD523C26EAQ40519749-3198B489-90C5-4AFA-9C1E-FB7171D3A04CQ41862279-0B42DBC6-54F5-42B3-88DF-C0BD36EE413FQ41927589-09D3DDDF-B993-4CAC-8CB1-9A7F90170558Q41963250-083A285A-9F3E-4CD1-8193-CCF6CDC39B2CQ44962277-2DA568D7-D363-4A00-80E0-F4EB1196A901Q45925037-123F1B47-6815-42AC-9A80-FC972B687F99Q46562116-E731CBAD-DA2B-494E-A80B-81F04DCFF135Q47549153-7F8E33CC-C3D1-4461-859F-42EC9D699F9CQ47559421-B1DF3B47-845F-4A47-B07C-A6CCAB14CCDEQ49762357-7162BC7F-C4D3-459C-BC4A-D17C8185F86FQ52313079-E575A5ED-EDC7-4B5D-90AA-69CC09387CA2Q52566938-FAD69D55-7CD6-49A7-812E-769AFD20EDD7Q52598776-170492F5-1AAE-48AE-A988-A0B5591BC5C4Q52738940-62214DDC-AE22-4784-A562-D51AF18ECADCQ54214221-019F9C22-CB1A-40F5-A886-59B3B4EA6576Q55347049-BB87B481-3597-4529-96BD-1DCEEAC527CBQ57071746-6436F4AC-D82C-4801-8527-F174D41D2564Q58038937-AA55C01C-3078-4C39-B096-7869F7FF1721Q60959639-D7A6CB54-4EC2-4AB4-B222-2CBCF1B57D8AQ61228981-4BEC1331-E021-4101-8613-232256B9CC43Q64063774-52E4ACC4-68E9-47CB-BF50-323784922353
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Nigel Garrett
@ast
Nigel Garrett
@en
Nigel Garrett
@es
Nigel Garrett
@nl
type
label
Nigel Garrett
@ast
Nigel Garrett
@en
Nigel Garrett
@es
Nigel Garrett
@nl
prefLabel
Nigel Garrett
@ast
Nigel Garrett
@en
Nigel Garrett
@es
Nigel Garrett
@nl
P106
P21
P31
P496
0000-0002-4530-234X